🔗 Share this article

As the United States proceeds with historic adjustments to its vaccination guidelines, one figure has emerged somewhat surprisingly: Høeg, a US-based physician and epidemiologist who rose to prominence by questioning COVID-19 vaccines throughout the global health crisis and has focused upon possible deaths following Covid vaccination in her recent position at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Program

Agency leaders planned to reveal radical revisions to the childhood vaccination calendar in December, aligning the US with the Danish national calendar, it is understood – a substantial departure that would place the US at odds with many the international standard with little proof for improved outcomes. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Høeg is set to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the center this year.

A Shift at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics centers as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US to become more similar to Denmark's approach, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Questions Over Expertise

Dr. Høeg has no apparent track record in drug development, regulation or leadership, which has been customary for former leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since March.

“She appears not to have the necessary background” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in running a major agency. She lacks background in industry regulation.”

Past commissioners of the center would “understand laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that prior appointees who headed CBER have had.”

This division has an vast portfolio at the FDA, the former commissioner stated.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these must be looked after,” she noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the job, which supervises in excess of 5,000 employees. “It is a huge leadership role, if you perform it correctly,” the former official added.

Official Statement and Contentious Programs

When asked about inquiries about Høeg’s fitness for the role and whether this appointment indicates more teamwork among FDA leaders on immunizations, a press secretary stated that the “questions are based on flawed premises”.

“This background matches the duties of her job,” the official said, noting the months Dr. Høeg spent counseling the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a disputed one-day medication authorization process that reportedly concerned her predecessors. “How are these medications being selected for this voucher program? Who makes the choices?” Howard said. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, except for vaccines.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, track record, critics have noted. She authored a study using non-validated volunteer-provided data to estimate the frequency of heart inflammation after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming federal leadership encompassed revising guidelines for novel immunizations and ending “optional” vaccines, she stated after the election on a podcast. At the agency, Høeg has reportedly suggested barring teenage boys from getting Covid vaccines.

“She’s an complete ideologue who begins with her beliefs and tailors the evidence to retrofit the evidence in a highly disingenuous, fraudulent way,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|